NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives

(19)

(11)

EP 1 398 029 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION

(48)	Corrigendum issued on:
	16.06.2004 Bulletin 2004/25

(43)	Date of publication:
	17.03.2004 Bulletin 2004/12

(21)	Application number: 02020256.0

(22)	Date of filing: 10.09.2002

(51)	International Patent Classification (IPC)⁷: A61K 31/4155, A61K 31/415, C07D 405/04

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
	Designated Extension States:
	AL LT LV MK RO SI

(71)	Applicant: LION bioscience AG
	69123 Heidelberg (DE)

(72)	Inventors:
	Deuschle, Ulrich 69245 Bammental (DE) Heck, Stefanie 69120 Heidelberg (DE) Kober, Ingo 69251 Gaiberg (DE) Bauer, Ulrike 69207 Sandhausen (DE) Balogh, Imola 69469 Weinheim (DE)

(74)	Representative: Goddar, Heinz J., Dr. et al
	FORRESTER & BOEHMERT Pettenkoferstrasse 20-22 80336 München 80336 München (DE)

(54)	NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives

(57) The present invention relates to compounds according to the general formula (1) which bind to the NR3B1 receptor and act as antagonists of the NR3B1 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.